Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Characterising B cell numbers and memory B cells in HIV infected and uninfected Malawian adults

Authors: Herbert Longwe, Stephen Gordon, Rose Malamba, Neil French

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Untreated human immunodeficiency virus (HIV) disease disrupts B cell populations causing reduced memory and reduced naïve resting B cells leading to increases in specific co-infections and impaired responses to vaccines. To what extent antiretroviral treatment reverses these changes in an African population is uncertain.

Methods

A cross-sectional study was performed. We recruited HIV-uninfected and HIV-infected Malawian adults both on and off antiretroviral therapy attending the Queen Elizabeth Central hospital in Malawi. Using flow cytometry, we enumerated B cells and characterized memory B cells and compared these measurements by the different recruitment groups.

Results

Overall 64 participants were recruited - 20 HIV uninfected (HIV-), 30 HIV infected ART naïve (HIV+N) and 14 HIV-infected ART treated (HIV+T). ART treatment had been taken for a median of 33 months (Range 12-60 months). Compared to HIV- the HIV+N adults had low absolute number of naïve resting B cells (111 vs. 180 cells/μl p = 0.008); reduced memory B cells (27 vs. 51 cells/μl p = 0.0008). The HIV+T adults had B-cell numbers similar to HIV- except for memory B cells that remained significantly lower (30 vs. 51 cells/μl p = 0.02). In the HIV+N group we did not find an association between CD4 count and B cell numbers.

Conclusions

HIV infected Malawian adults have abnormal B-cell numbers. Individuals treated with ART show a return to normal in B-cell numbers but a persistent deficit in the memory subset is noted. This has important implications for long term susceptibility to co-infections and should be evaluated further in a larger cohort study.
Appendix
Available only for authorised users
Literature
1.
go back to reference French N, Moore M, Haikala R, Kayhty H, Gilks CF: A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis. 2004, 190 (4): 707-712. 10.1086/421911.CrossRefPubMed French N, Moore M, Haikala R, Kayhty H, Gilks CF: A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis. 2004, 190 (4): 707-712. 10.1086/421911.CrossRefPubMed
2.
go back to reference Klugman KP, Madhi SA, Feldman C: HIV and pneumococcal disease. Curr Opin Infect Dis. 2007, 20 (1): 11-15. 10.1097/QCO.0b013e328012c5f1.CrossRefPubMed Klugman KP, Madhi SA, Feldman C: HIV and pneumococcal disease. Curr Opin Infect Dis. 2007, 20 (1): 11-15. 10.1097/QCO.0b013e328012c5f1.CrossRefPubMed
3.
go back to reference French N, Gilks C: Pneumococcal Disease. Manson's Tropical Diseases. Edited by: Cook GC, Zumla AI. 2003, Elsevier, 21 French N, Gilks C: Pneumococcal Disease. Manson's Tropical Diseases. Edited by: Cook GC, Zumla AI. 2003, Elsevier, 21
4.
go back to reference Richard Y, Lefevre E, Krzysiek R: B cells in the line of sight of HIV-1. Cellular Aspects of HIV Infection. Edited by: Cossarizza A, Kaplan D. 2002, New York: Wiley InterScience, 69-102. Richard Y, Lefevre E, Krzysiek R: B cells in the line of sight of HIV-1. Cellular Aspects of HIV Infection. Edited by: Cossarizza A, Kaplan D. 2002, New York: Wiley InterScience, 69-102.
5.
go back to reference Townsley-Fuchs J, Neshat MS, Margolin DH, Braun J, Goodglick L: HIV-1 gp120: a novel viral B cell superantigen. Int Rev Immunol. 1997, 14 (4): 325-338.CrossRefPubMed Townsley-Fuchs J, Neshat MS, Margolin DH, Braun J, Goodglick L: HIV-1 gp120: a novel viral B cell superantigen. Int Rev Immunol. 1997, 14 (4): 325-338.CrossRefPubMed
6.
go back to reference Dawood MR, Conway B, Patenaude P, Janmohamed F, Montaner JS, O'Shaughnessy MV, Hammond GW: Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients. J Clin Immunol. 1998, 18 (3): 235-240. 10.1023/A:1020539207593.CrossRefPubMed Dawood MR, Conway B, Patenaude P, Janmohamed F, Montaner JS, O'Shaughnessy MV, Hammond GW: Association of phenotypic changes in B cell lymphocytes and plasma viral load in human immunodeficiency virus-infected patients. J Clin Immunol. 1998, 18 (3): 235-240. 10.1023/A:1020539207593.CrossRefPubMed
7.
go back to reference De Milito A, Morch C, Sonnerborg A, Chiodi F: Loss of memory (CD27) B lymphocytes in HIV-1 infection. Aids. 2001, 15 (8): 957-964. 10.1097/00002030-200105250-00003.CrossRefPubMed De Milito A, Morch C, Sonnerborg A, Chiodi F: Loss of memory (CD27) B lymphocytes in HIV-1 infection. Aids. 2001, 15 (8): 957-964. 10.1097/00002030-200105250-00003.CrossRefPubMed
8.
go back to reference Jacobsen MC, Thiebaut R, Fisher C, Sefe D, Clapson M, Klein N, Baxendale HE: Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. J Infect Dis. 2008, 198 (4): 481-485. 10.1086/590215.CrossRefPubMed Jacobsen MC, Thiebaut R, Fisher C, Sefe D, Clapson M, Klein N, Baxendale HE: Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. J Infect Dis. 2008, 198 (4): 481-485. 10.1086/590215.CrossRefPubMed
9.
go back to reference Chong Y, Ikematsu H, Yamamoto M, Murata M, Yamaji K, Nishimura M, Nabeshima S, Kashiwagi S, Hayashi J: Increased frequency of CD27- (naive) B cells and their phenotypic alteration in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2004, 20 (6): 621-629. 10.1089/0889222041217455.CrossRefPubMed Chong Y, Ikematsu H, Yamamoto M, Murata M, Yamaji K, Nishimura M, Nabeshima S, Kashiwagi S, Hayashi J: Increased frequency of CD27- (naive) B cells and their phenotypic alteration in HIV type 1-infected patients. AIDS Res Hum Retroviruses. 2004, 20 (6): 621-629. 10.1089/0889222041217455.CrossRefPubMed
10.
go back to reference Deterre P, Berthelier V, Bauvois B, Dalloul A, Schuber F, Lund F: CD38 in T- and B-cell functions. Chem Immunol. 2000, 75: 146-168. full_text.CrossRefPubMed Deterre P, Berthelier V, Bauvois B, Dalloul A, Schuber F, Lund F: CD38 in T- and B-cell functions. Chem Immunol. 2000, 75: 146-168. full_text.CrossRefPubMed
11.
go back to reference Moir S, Fauci AS: Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol. 2008, 122 (1): 12-19. 10.1016/j.jaci.2008.04.034. quiz 20-11CrossRefPubMedPubMedCentral Moir S, Fauci AS: Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol. 2008, 122 (1): 12-19. 10.1016/j.jaci.2008.04.034. quiz 20-11CrossRefPubMedPubMedCentral
13.
go back to reference Fournier AM, Baillat V, Alix-Panabieres C, Fondere JM, Merle C, Segondy M, Huguet MF, Reynes J, Vendrell JP: Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. Aids. 2002, 16 (13): 1755-1760. 10.1097/00002030-200209060-00007.CrossRefPubMed Fournier AM, Baillat V, Alix-Panabieres C, Fondere JM, Merle C, Segondy M, Huguet MF, Reynes J, Vendrell JP: Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. Aids. 2002, 16 (13): 1755-1760. 10.1097/00002030-200209060-00007.CrossRefPubMed
14.
go back to reference Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O'Shea MA, Roby G, Mican JM, Kottilil S, Chun TW, et al: Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008, 197 (4): 572-579. 10.1086/526789.CrossRefPubMed Moir S, Malaspina A, Ho J, Wang W, Dipoto AC, O'Shea MA, Roby G, Mican JM, Kottilil S, Chun TW, et al: Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis. 2008, 197 (4): 572-579. 10.1086/526789.CrossRefPubMed
15.
go back to reference Nilssen DE, Oktedalen O, Brandtzaeg P: Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy. Gut. 2004, 53 (4): 487-493. 10.1136/gut.2003.027854.CrossRefPubMedPubMedCentral Nilssen DE, Oktedalen O, Brandtzaeg P: Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy. Gut. 2004, 53 (4): 487-493. 10.1136/gut.2003.027854.CrossRefPubMedPubMedCentral
16.
go back to reference Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, Cremers J, Hellings JA, Danner SA, de Ronde A: Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses. 2001, 17 (11): 1003-1008. 10.1089/088922201300343681.CrossRefPubMed Notermans DW, de Jong JJ, Goudsmit J, Bakker M, Roos MT, Nijholt L, Cremers J, Hellings JA, Danner SA, de Ronde A: Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses. 2001, 17 (11): 1003-1008. 10.1089/088922201300343681.CrossRefPubMed
17.
go back to reference Beniguel L, Begaud E, Cognasse F, Gabrie P, Mbolidi CD, Sabido O, Marovich MA, DeFontaine C, Fresard A, Lucht F, et al: Identification of germinal center B cells in blood from HIV-infected drug-naive individuals in Central Africa. Clin Dev Immunol. 2004, 11 (1): 23-27. 10.1080/10446670410001670454.CrossRefPubMedPubMedCentral Beniguel L, Begaud E, Cognasse F, Gabrie P, Mbolidi CD, Sabido O, Marovich MA, DeFontaine C, Fresard A, Lucht F, et al: Identification of germinal center B cells in blood from HIV-infected drug-naive individuals in Central Africa. Clin Dev Immunol. 2004, 11 (1): 23-27. 10.1080/10446670410001670454.CrossRefPubMedPubMedCentral
18.
go back to reference Berberian L, Goodglick L, Kipps TJ, Braun J: Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science. 1993, 261 (5128): 1588-1591. 10.1126/science.7690497.CrossRefPubMed Berberian L, Goodglick L, Kipps TJ, Braun J: Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science. 1993, 261 (5128): 1588-1591. 10.1126/science.7690497.CrossRefPubMed
19.
go back to reference Agematsu K, Hokibara S, Nagumo H, Komiyama A: CD27: a memory B-cell marker. Immunol Today. 2000, 21 (5): 204-206. 10.1016/S0167-5699(00)01605-4.CrossRefPubMed Agematsu K, Hokibara S, Nagumo H, Komiyama A: CD27: a memory B-cell marker. Immunol Today. 2000, 21 (5): 204-206. 10.1016/S0167-5699(00)01605-4.CrossRefPubMed
20.
go back to reference D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA: Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. Aids. 2007, 21 (13): 1747-1752. 10.1097/QAD.0b013e32828642c7.CrossRefPubMed D'Orsogna LJ, Krueger RG, McKinnon EJ, French MA: Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy. Aids. 2007, 21 (13): 1747-1752. 10.1097/QAD.0b013e32828642c7.CrossRefPubMed
21.
go back to reference Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM: Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. Aids. 2006, 20 (3): 437-444. 10.1097/01.aids.0000206507.54901.84.CrossRefPubMed Barry PM, Zetola N, Keruly JC, Moore RD, Gebo KA, Lucas GM: Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003. Aids. 2006, 20 (3): 437-444. 10.1097/01.aids.0000206507.54901.84.CrossRefPubMed
Metadata
Title
Characterising B cell numbers and memory B cells in HIV infected and uninfected Malawian adults
Authors
Herbert Longwe
Stephen Gordon
Rose Malamba
Neil French
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-280

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine